破解黑色素瘤的盔甲:对XPO1和β-catenin进行超分子双重打击,以克服抵抗力
Yinliang Lu1, Ruishan Guo1, Wenfei Song1
1Department of Radiation Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Journal of advanced research
|March 5, 2025
概括
这项研究开发了XPinβ,这是一种针对黑色素瘤的新型双治疗方法,可以抑制XPO1和β-catenin,克服对XPO1抑制剂的耐药性,并显著抑制瘤生长和转移.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物输送系统 药物输送系统
背景情况:
- 过度表达XPO1与黑色素瘤的预后不佳有关,使其成为治疗点.
- 针对XPO1的单一疗法在黑色素瘤治疗中显示出有限的疗效.
- 了解XPO1耐药机制对于开发有效的黑色素瘤疗法至关重要.
研究的目的:
- 研究黑色素瘤中XPO1向治疗的耐药性机制.
- 开发一种新的蛋白质微球 (XPinβ),用于XPO1和β-catenin的双重向.
- 在黑色素瘤中增强XPO1抑制剂的治疗疗效.
主要方法:
- 转录组测序以分析XPO1干扰对黑色素瘤信号通路的影响.
- 核细胞质蛋白分离,共免疫沉和共聚焦显微镜以阐明抗性机制.
- 在细胞,异种移植和患者衍生异种移植 (PDX) 模型中,制造和评估XPinβ,一个共组装XPO1和β-catenin对手的微球.
主要成果:
- 抑制XPO1激活了Wnt/β-catenin通路,从而导致β-catenin的核积累.
- XPinβ有效地准XPO1和β-catenin,在临床前模型中显示出与单一疗法相比更高的抗瘤活性.
- 在PDX模型中,XPinβ显著抑制了黑色素瘤的生长,并抑制了肺转移,具有良好的生物安全性.
结论:
- 对XPO1和Wnt/β-catenin通路的双重向提高了黑色素瘤的治疗疗效.
- XPinβ代表了一种有前途的双重向策略,用于治疗黑色素瘤,具有临床翻译潜力.
- 这种方法克服了XPO1抑制剂的耐药性,并为黑色素瘤提供了新的治疗途径.
更多相关视频
08:18Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
2.9K
07:41A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
2.4K
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Catenins
2.3K
Catenins are characterized by multiple binding domains and dynamic structures that allow them to function as linker proteins in cell junction complexes. All catenins, except α-catenin, contain a characteristic protein sequence called the armadillo repeat and are therefore also called armadillo proteins.
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the...
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the...
2.3K
The Intrinsic Apoptotic Pathway
5.9K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.9K
Cancer Cell Migration through Invadopodia
2.3K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.3K
